Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 161 articles:
HTML format
Text format



Single Articles


    June 2017
  1. GRINDEDAL EM, Heramb C, Karsrud I, Ariansen SL, et al
    Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    BMC Cancer. 2017;17:438.
    PubMed     Text format     Abstract available


  2. JACQUINOT Q, Meneveau N, Chatot M, Bonnetain F, et al
    A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    BMC Cancer. 2017;17:425.
    PubMed     Text format     Abstract available


  3. OZAKI A, Nomura S, Leppold C, Tsubokura M, et al
    Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.
    BMC Cancer. 2017;17:423.
    PubMed     Text format     Abstract available


  4. ZANOTTI G, Hunger M, Perkins JJ, Horblyuk R, et al
    Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
    BMC Cancer. 2017;17:393.
    PubMed     Text format     Abstract available


    May 2017
  5. YOO TK, Chang JM, Shin HC, Han W, et al
    An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment.
    BMC Cancer. 2017;17:389.
    PubMed     Text format     Abstract available


  6. DE BONIFACE J, Frisell J, Andersson Y, Bergkvist L, et al
    Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
    BMC Cancer. 2017;17:379.
    PubMed     Text format     Abstract available


  7. WANG F, Tse LA, Chan WC, Kwok CC, et al
    Disparities of time trends and birth cohort effects on invasive breast cancer incidence in Shanghai and Hong Kong pre- and post-menopausal women.
    BMC Cancer. 2017;17:362.
    PubMed     Text format     Abstract available


  8. WILLIAMS V, Grosset AA, Zamorano Cuervo N, St-Pierre Y, et al
    Detection of IKKepsilon by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis.
    BMC Cancer. 2017;17:356.
    PubMed     Text format     Abstract available


  9. KUROZUMI S, Matsumoto H, Hayashi Y, Tozuka K, et al
    Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    BMC Cancer. 2017;17:354.
    PubMed     Text format     Abstract available


  10. LAMBERTINI M, Anserini P, Fontana V, Poggio F, et al
    The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients.
    BMC Cancer. 2017;17:346.
    PubMed     Text format     Abstract available


  11. ZHANG S, Zhang D, Gong M, Wen L, et al
    High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer.
    BMC Cancer. 2017;17:335.
    PubMed     Text format     Abstract available


  12. LAGENDIJK M, Vos EL, Koning AHJ, Hunink MGM, et al
    TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial.
    BMC Cancer. 2017;17:336.
    PubMed     Text format     Abstract available


  13. DELGADO-GARCIA S, Martinez-Escoriza JC, Alba A, Martin-Bayon TA, et al
    Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study.
    BMC Cancer. 2017;17:320.
    PubMed     Text format     Abstract available


  14. VAN BOMMEL RMG, Weber R, Voogd AC, Nederend J, et al
    Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography.
    BMC Cancer. 2017;17:315.
    PubMed     Text format     Abstract available


  15. MARK KMK, Varn FS, Ung MH, Qian F, et al
    The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
    BMC Cancer. 2017;17:306.
    PubMed     Text format     Abstract available


  16. MU J, Zhu D, Shen Z, Ning S, et al
    The repressive effect of miR-148a on Wnt/beta-catenin signaling involved in Glabridin-induced anti-angiogenesis in human breast cancer cells.
    BMC Cancer. 2017;17:307.
    PubMed     Text format     Abstract available


    April 2017
  17. ZHU J, Ebert L, Liu X, Chan SW, et al
    A mobile application of breast cancer e-support program versus routine Care in the treatment of Chinese women with breast cancer undergoing chemotherapy: study protocol for a randomized controlled trial.
    BMC Cancer. 2017;17:291.
    PubMed     Text format     Abstract available


  18. SETYOWIBOWO H, Sijbrandij M, Iskandarsyah A, Hunfeld JAM, et al
    A protocol for a cluster-randomized controlled trial of a self-help psycho-education programme to reduce diagnosis delay in women with breast cancer symptoms in Indonesia.
    BMC Cancer. 2017;17:284.
    PubMed     Text format     Abstract available


  19. LABOVSKY V, Martinez LM, Davies KM, de Lujan Calcagno M, et al
    Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.
    BMC Cancer. 2017;17:280.
    PubMed     Text format     Abstract available


  20. CHAN S, Chen JH, Li S, Chang R, et al
    Evaluation of the association between quantitative mammographic density and breast cancer occurred in different quadrants.
    BMC Cancer. 2017;17:274.
    PubMed     Text format     Abstract available


  21. PESTALOZZI BC, Tausch C, Dedes KJ, Rochlitz C, et al
    Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
    BMC Cancer. 2017;17:265.
    PubMed     Text format     Abstract available


  22. VAN DEN BERG MM, Winkels RM, de Kruif JT, van Laarhoven HW, et al
    Weight change during chemotherapy in breast cancer patients: a meta-analysis.
    BMC Cancer. 2017;17:259.
    PubMed     Text format     Abstract available


  23. SPITZWIESER M, Entfellner E, Werner B, Pulverer W, et al
    Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
    BMC Cancer. 2017;17:260.
    PubMed     Text format     Abstract available


  24. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    PubMed     Text format     Abstract available


  25. JOVANOVIC B, Sheng Q, Seitz RS, Lawrence KD, et al
    Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.
    BMC Cancer. 2017;17:241.
    PubMed     Text format     Abstract available


  26. MELVIN JC, Garmo H, Holmberg L, Hammar N, et al
    Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.
    BMC Cancer. 2017;17:246.
    PubMed     Text format     Abstract available


    March 2017
  27. ARIAANS G, Jalving M, Vries EG, Jong S, et al
    Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
    BMC Cancer. 2017;17:232.
    PubMed     Text format     Abstract available


  28. KURBEL S, Dmitrovic B, Marjanovic K, Vrbanec D, et al
    Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology.
    BMC Cancer. 2017;17:231.
    PubMed     Text format     Abstract available


  29. OBERGUGGENBERGER A, Meraner V, Sztankay M, Beer B, et al
    Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
    BMC Cancer. 2017;17:226.
    PubMed     Text format     Abstract available


  30. GARCIA-SAENZ JA, Ayllon P, Laig M, Acosta-Eyzaguirre D, et al
    Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
    BMC Cancer. 2017;17:210.
    PubMed     Text format     Abstract available


  31. PETERS IT, van der Steen MA, Huisman BW, Hilders CG, et al
    Morphological and phenotypical features of ovarian metastases in breast cancer patients.
    BMC Cancer. 2017;17:206.
    PubMed     Text format     Abstract available


  32. PADRO M, Louie RJ, Lananna BV, Krieg AJ, et al
    Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2017;17:203.
    PubMed     Text format     Abstract available


  33. LIM JP, Shyamasundar S, Gunaratne J, Scully OJ, et al
    YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.
    BMC Cancer. 2017;17:201.
    PubMed     Text format     Abstract available


  34. DODOVA RI, Mitkova AV, Dacheva DR, Hadjo LB, et al
    Erratum to: Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    BMC Cancer. 2017;17:195.
    PubMed     Text format    


  35. HUANG Y, Burns DJ, Rich BE, MacNeil IA, et al
    Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
    BMC Cancer. 2017;17:199.
    PubMed     Text format     Abstract available


  36. DOS SANTOS AF, Terra LF, Wailemann RA, Oliveira TC, et al
    Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells.
    BMC Cancer. 2017;17:194.
    PubMed     Text format     Abstract available


  37. CHARAGHVANDI RK, van Asselen B, Philippens ME, Verkooijen HM, et al
    Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.
    BMC Cancer. 2017;17:181.
    PubMed     Text format     Abstract available


  38. KROZ M, Reif M, Glinz A, Berger B, et al
    Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design.
    BMC Cancer. 2017;17:166.
    PubMed     Text format     Abstract available


    February 2017
  39. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    BMC Cancer. 2017;17:160.
    PubMed     Text format     Abstract available


  40. MORRIS M, Woods LM, Bhaskaran K, Rachet B, et al
    Do pre-diagnosis primary care consultation patterns explain deprivation-specific differences in net survival among women with breast cancer? An examination of individually-linked data from the UK West Midlands cancer registry, national screening progr
    BMC Cancer. 2017;17:155.
    PubMed     Text format     Abstract available


  41. MCKINNON CM, Mellor H
    The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B.
    BMC Cancer. 2017;17:145.
    PubMed     Text format     Abstract available


  42. SINN HP, Schneeweiss A, Keller M, Schlombs K, et al
    Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    BMC Cancer. 2017;17:124.
    PubMed     Text format     Abstract available


  43. EFFI AB, Aman NA, Koui BS, Koffi KD, et al
    Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    BMC Cancer. 2017;17:115.
    PubMed     Text format     Abstract available


  44. JAISWAL R, Johnson MS, Pokharel D, Krishnan SR, et al
    Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion.
    BMC Cancer. 2017;17:104.
    PubMed     Text format     Abstract available


  45. WENGSTROM Y, Bolam KA, Mijwel S, Sundberg CJ, et al
    Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy.
    BMC Cancer. 2017;17:100.
    PubMed     Text format     Abstract available


  46. BARBA M, Vici P, Pizzuti L, Di Lauro L, et al
    Body mass index modifies the relationship between gamma-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
    BMC Cancer. 2017;17:101.
    PubMed     Text format     Abstract available


    January 2017
  47. LAVENDER N, Yang J, Chen SC, Sai J, et al
    The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo.
    BMC Cancer. 2017;17:88.
    PubMed     Text format     Abstract available


  48. VIERKANT RA, Degnim AC, Radisky DC, Visscher DW, et al
    Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.
    BMC Cancer. 2017;17:84.
    PubMed     Text format     Abstract available


  49. AUGUSTIN LS, Libra M, Crispo A, Grimaldi M, et al
    Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial.
    BMC Cancer. 2017;17:69.
    PubMed     Text format     Abstract available


  50. VESUNA F, Bergman Y, Raman V
    Genomic pathways modulated by Twist in breast cancer.
    BMC Cancer. 2017;17:52.
    PubMed     Text format     Abstract available


  51. NANDI P, Girish GV, Majumder M, Xin X, et al
    PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
    BMC Cancer. 2017;17:11.
    PubMed     Text format     Abstract available


  52. SORENSEN KM, Meldgaard T, Melchjorsen CJ, Fridriksdottir AJ, et al
    Upregulation of Mrps18a in breast cancer identified by selecting phage antibody libraries on breast tissue sections.
    BMC Cancer. 2017;17:19.
    PubMed     Text format     Abstract available


  53. SHACHAR SS, Mashiach T, Fried G, Drumea K, et al
    Biopsy of breast cancer metastases: patient characteristics and survival.
    BMC Cancer. 2017;17:7.
    PubMed     Text format     Abstract available


    December 2016
  54. SCHULER-TOPRAK S, Haring J, Inwald EC, Moehle C, et al
    Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro.
    BMC Cancer. 2016;16:951.
    PubMed     Text format     Abstract available


  55. GIBBONS A, Groarke A, Sweeney K
    Predicting general and cancer-related distress in women with newly diagnosed breast cancer.
    BMC Cancer. 2016;16:935.
    PubMed     Text format     Abstract available


  56. LIN FP, Pokorny A, Teng C, Dear R, et al
    Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach.
    BMC Cancer. 2016;16:929.
    PubMed     Text format     Abstract available


    November 2016
  57. HONG R, Ma F, Zhang W, Yu X, et al
    Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    BMC Cancer. 2016;16:925.
    PubMed     Text format    


  58. ARPINO G, Pensabene M, Condello C, Ruocco R, et al
    Tumor characteristics and prognosis in familial breast cancer.
    BMC Cancer. 2016;16:924.
    PubMed     Text format     Abstract available


  59. VANKLOMPENBERG MK, Bedalov CO, Soto KF, Prosperi JR, et al
    Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancer.
    BMC Cancer. 2016;16:921.
    PubMed     Text format    


  60. ATEMA V, van Leeuwen M, Oldenburg HS, Retel V, et al
    Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.
    BMC Cancer. 2016;16:920.
    PubMed     Text format     Abstract available


  61. KOSALOGLU Z, Bitzer J, Halama N, Huang Z, et al
    In silico SNP analysis of the breast cancer antigen NY-BR-1.
    BMC Cancer. 2016;16:901.
    PubMed     Text format     Abstract available


  62. MAGNUSSON K, Gremel G, Ryden L, Ponten V, et al
    ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
    BMC Cancer. 2016;16:904.
    PubMed     Text format     Abstract available


  63. WANG Y, Chen L, Wu Z, Wang M, et al
    miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL.
    BMC Cancer. 2016;16:826.
    PubMed     Text format     Abstract available


  64. CHEN J, Shin VY, Siu MT, Ho JC, et al
    miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    BMC Cancer. 2016;16:887.
    PubMed     Text format     Abstract available


  65. GEIGER P, Mayer B, Wiest I, Schulze S, et al
    Binding of galectin-1 to breast cancer cells MCF7 induces apoptosis and inhibition of proliferation in vitro in a 2D- and 3D- cell culture model.
    BMC Cancer. 2016;16:870.
    PubMed     Text format     Abstract available


  66. MONROY-CISNEROS K, Esparza-Romero J, Valencia ME, Guevara-Torres AG, et al
    Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.
    BMC Cancer. 2016;16:860.
    PubMed     Text format     Abstract available


  67. BLODT S, Mittring N, Schutzler L, Fischer F, et al
    A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study.
    BMC Cancer. 2016;16:843.
    PubMed     Text format     Abstract available


  68. WINSLOW S, Lindquist KE, Edsjo A, Larsson C, et al
    The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer.
    BMC Cancer. 2016;16:841.
    PubMed     Text format     Abstract available


  69. SHEN CC, Hu LY, Yang AC, Chiang YY, et al
    Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
    BMC Cancer. 2016;16:839.
    PubMed     Text format     Abstract available


  70. MASARWAH A, Auvinen P, Sudah M, Dabravolskaite V, et al
    Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
    BMC Cancer. 2016;16:833.
    PubMed     Text format     Abstract available


    October 2016
  71. REEVES MM, Terranova CO, Erickson JM, Job JR, et al
    Living well after breast cancer randomized controlled trial protocol: evaluating a telephone-delivered weight loss intervention versus usual care in women following treatment for breast cancer.
    BMC Cancer. 2016;16:830.
    PubMed     Text format     Abstract available


  72. WOLF B, Goebel G, Hackl H, Fiegl H, et al
    Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
    BMC Cancer. 2016;16:821.
    PubMed     Text format     Abstract available


  73. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2016;16:819.
    PubMed     Text format     Abstract available


  74. MIAO H, Hartman M, Verkooijen HM, Taib NA, et al
    Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia.
    BMC Cancer. 2016;16:820.
    PubMed     Text format     Abstract available


  75. ZHOU Y, Lin S, Tseng KF, Han K, et al
    Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
    BMC Cancer. 2016;16:818.
    PubMed     Text format     Abstract available


  76. BECKER MA, Hou X, Tienchaianada P, Haines BB, et al
    Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    BMC Cancer. 2016;16:814.
    PubMed     Text format     Abstract available


  77. YU Y, Cui N, Li HY, Wu YM, et al
    Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine n
    BMC Cancer. 2016;16:808.
    PubMed     Text format     Abstract available


  78. NEKULOVA M, Holcakova J, Gu X, Hrabal V, et al
    DeltaNp63alpha expression induces loss of cell adhesion in triple-negative breast cancer cells.
    BMC Cancer. 2016;16:782.
    PubMed     Text format     Abstract available


  79. ROCHLITZ C, Bigler M, von Moos R, Bernhard J, et al
    SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase II
    BMC Cancer. 2016;16:780.
    PubMed     Text format     Abstract available


    February 2016
  80. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    PubMed     Text format     Abstract available


  81. NOLAN RM, Adie SG, Marjanovic M, Chaney EJ, et al
    Intraoperative optical coherence tomography for assessing human lymph nodes for metastatic cancer.
    BMC Cancer. 2016;16:144.
    PubMed     Text format     Abstract available


    January 2016
  82. DIESSNER J, Wischnewsky M, Stuber T, Stein R, et al
    Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    BMC Cancer. 2016;16:307.
    PubMed     Text format     Abstract available


  83. HENDERSON SL, Teft WA, Kim RB
    Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFalpha biologic for ulcerative colitis: a case report.
    BMC Cancer. 2016;16:304.
    PubMed     Text format     Abstract available


  84. SOMASUNDARAM V, Hemalatha SK, Pal K, Sinha S, et al
    Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    BMC Cancer. 2016;16:336.
    PubMed     Text format     Abstract available


  85. MOSLEHI R, Freedman E, Zeinomar N, Veneroso C, et al
    Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study.
    BMC Cancer. 2016;16:334.
    PubMed     Text format     Abstract available


  86. BAZZI ZA, Lanoue D, El-Youssef M, Romagnuolo R, et al
    Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    BMC Cancer. 2016;16:328.
    PubMed     Text format     Abstract available


  87. CLARE SE, Gupta A, Choi M, Ranjan M, et al
    Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes.
    BMC Cancer. 2016;16:326.
    PubMed     Text format     Abstract available


  88. CHEN Y, Chen K, Xiao X, Nie Y, et al
    Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    BMC Cancer. 2016;16:320.
    PubMed     Text format     Abstract available


  89. KIM HA, Ahn SH, Nam SJ, Park S, et al
    The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
    BMC Cancer. 2016;16:319.
    PubMed     Text format     Abstract available


  90. ARROSPIDE A, Rue M, van Ravesteyn NT, Comas M, et al
    Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    BMC Cancer. 2016;16:344.
    PubMed     Text format     Abstract available


  91. GANGADHARA S, Smith C, Barrett-Lee P, Hiscox S, et al
    3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.
    BMC Cancer. 2016;16:345.
    PubMed     Text format     Abstract available


  92. CAO Y, Feng Y, Zhang Y, Zhu X, et al
    L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.
    BMC Cancer. 2016;16:343.
    PubMed     Text format     Abstract available


  93. REIMER T, Kempert S, Gerber B, Thiesen HJ, et al
    SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.
    BMC Cancer. 2016;16:337.
    PubMed     Text format     Abstract available


  94. GOLUBNITSCHAJA O, Yeghiazaryan K, Stricker H, Trog D, et al
    Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours.
    BMC Cancer. 2016;16:357.
    PubMed     Text format     Abstract available


  95. MAGHOUS A, Rais F, Ahid S, Benhmidou N, et al
    Factors influencing diagnosis delay of advanced breast cancer in Moroccan women.
    BMC Cancer. 2016;16:356.
    PubMed     Text format     Abstract available


  96. MILLER K, Cortes J, Hurvitz SA, Krop IE, et al
    HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer.
    BMC Cancer. 2016;16:352.
    PubMed     Text format     Abstract available


  97. BOUCHARD G, Therriault H, Geha S, Berube-Lauziere Y, et al
    Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
    BMC Cancer. 2016;16:361.
    PubMed     Text format     Abstract available


  98. JANSSON S, Bendahl PO, Larsson AM, Aaltonen KE, et al
    Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    BMC Cancer. 2016;16:433.
    PubMed     Text format     Abstract available


  99. LAIBLE M, Schlombs K, Kaiser K, Veltrup E, et al
    Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    BMC Cancer. 2016;16:398.
    PubMed     Text format     Abstract available


  100. DAVIES EA, Coupland VH, Dixon S, Mokbel K, et al
    Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer: pilot data exchange and analyses.
    BMC Cancer. 2016;16:421.
    PubMed     Text format     Abstract available


  101. KOBAYASHI T, Tomomatsu J, Fukada I, Shibayama T, et al
    Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
    BMC Cancer. 2016;16:404.
    PubMed     Text format     Abstract available


  102. LEE ES, Han W, Kim MK, Kim J, et al
    Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
    BMC Cancer. 2016;16:430.
    PubMed     Text format     Abstract available


  103. JUECKSTOCK J, Rack B, Friedl TW, Scholz C, et al
    Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    BMC Cancer. 2016;16:401.
    PubMed     Text format     Abstract available


  104. WINKEL RR, von Euler-Chelpin M, Nielsen M, Petersen K, et al
    Mammographic density and structural features can individually and jointly contribute to breast cancer risk assessment in mammography screening: a case-control study.
    BMC Cancer. 2016;16:414.
    PubMed     Text format     Abstract available


  105. YANG M, Ma B, Shao H, Clark AM, et al
    Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells.
    BMC Cancer. 2016;16:419.
    PubMed     Text format     Abstract available


  106. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum HER2 extra-cellular domain, S100ss and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
    BMC Cancer. 2016;16:428.
    PubMed     Text format     Abstract available


  107. KANGASPESKA S, Hultsch S, Jaiswal A, Edgren H, et al
    Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
    BMC Cancer. 2016;16:378.
    PubMed     Text format     Abstract available


  108. GARGIULO P, Pensabene M, Milano M, Arpino G, et al
    Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    BMC Cancer. 2016;16:375.
    PubMed     Text format     Abstract available


  109. FLORES-PEREZ A, Marchat LA, Rodriguez-Cuevas S, Bautista VP, et al
    Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells.
    BMC Cancer. 2016;16:379.
    PubMed     Text format     Abstract available


  110. YU X, Hu G, Zhang Z, Qiu F, et al
    Retrospective and comparative analysis of (99m)Tc-Sestamibi breast specific gamma imaging versus mammography, ultrasound, and magnetic resonance imaging for the detection of breast cancer in Chinese women.
    BMC Cancer. 2016;16:450.
    PubMed     Text format     Abstract available


  111. ZDUNIAK K, Agrawal A, Agrawal S, Hossain MM, et al
    Osteopontin splice variants are differential predictors of breast cancer treatment responses.
    BMC Cancer. 2016;16:441.
    PubMed     Text format     Abstract available


  112. DENG W, Wang Y, Gu L, Duan B, et al
    MICAL1 controls cell invasive phenotype via regulating oxidative stress in breast cancer cells.
    BMC Cancer. 2016;16:489.
    PubMed     Text format     Abstract available


  113. MARTINEZ JA, Chalasani P, Thomson CA, Roe D, et al
    Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    BMC Cancer. 2016;16:500.
    PubMed     Text format     Abstract available


  114. LUI A, New J, Ogony J, Thomas S, et al
    Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    BMC Cancer. 2016;16:487.
    PubMed     Text format     Abstract available


  115. COURNEYA KS, McNeely ML, Culos-Reed SN, Vallance JK, et al
    The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants.
    BMC Cancer. 2016;16:481.
    PubMed     Text format     Abstract available


  116. CHEN BB, Lu YS, Lin CH, Chen WW, et al
    A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    BMC Cancer. 2016;16:466.
    PubMed     Text format     Abstract available


  117. STEIN RG, Wollschlager D, Kreienberg R, Janni W, et al
    The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients.
    BMC Cancer. 2016;16:459.
    PubMed     Text format     Abstract available


  118. COCKBURN JG, Hallett RM, Gillgrass AE, Dias KN, et al
    The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
    BMC Cancer. 2016;16:555.
    PubMed     Text format     Abstract available


  119. AL-HOWAIL HA, Hakami HA, Al-Otaibi B, Al-Mazrou A, et al
    PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
    BMC Cancer. 2016;16:540.
    PubMed     Text format     Abstract available


  120. VILSMAIER T, Rack B, Janni W, Jeschke U, et al
    Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment.
    BMC Cancer. 2016;16:547.
    PubMed     Text format     Abstract available


  121. BAUMANN J, Wong J, Sun Y, Conklin DS, et al
    Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    BMC Cancer. 2016;16:551.
    PubMed     Text format     Abstract available


  122. WU LA, Kuo WH, Chen CY, Tsai YS, et al
    The association of infrared imaging findings of the breast with prognosis in breast cancer patients: an observational cohort study.
    BMC Cancer. 2016;16:541.
    PubMed     Text format     Abstract available


  123. ZHU J, Zhuang T, Yang H, Li X, et al
    Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression.
    BMC Cancer. 2016;16:538.
    PubMed     Text format     Abstract available


  124. AKTAS B, Kasimir-Bauer S, Muller V, Janni W, et al
    Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    BMC Cancer. 2016;16:522.
    PubMed     Text format     Abstract available


  125. ZHANG S, Li L, Wang T, Bian L, et al
    Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    BMC Cancer. 2016;16:526.
    PubMed     Text format     Abstract available


  126. PLOOS VAN AMSTEL FK, Prins JB, van der Graaf WT, Peters ME, et al
    The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial.
    BMC Cancer. 2016;16:520.
    PubMed     Text format     Abstract available


  127. VAN HELMONDT SJ, van der Lee ML, de Vries J
    Study protocol of the CAREST-trial: a randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer.
    BMC Cancer. 2016;16:527.
    PubMed     Text format     Abstract available


  128. BLOOMQUIST K, Hayes S, Adamsen L, Moller T, et al
    A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol.
    BMC Cancer. 2016;16:517.
    PubMed     Text format     Abstract available


  129. YANG Y, Im SA, Keam B, Lee KH, et al
    Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
    BMC Cancer. 2016;16:515.
    PubMed     Text format     Abstract available


  130. BERNAL-ESTEVEZ D, Sanchez R, Tejada RE, Parra-Lopez C, et al
    Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.
    BMC Cancer. 2016;16:591.
    PubMed     Text format     Abstract available


  131. CHOI SK, Kim HS, Jin T, Hwang EH, et al
    Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    BMC Cancer. 2016;16:570.
    PubMed     Text format     Abstract available


  132. SHE QB, Gruvberger-Saal SK, Maurer M, Chen Y, et al
    Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    BMC Cancer. 2016;16:587.
    PubMed     Text format     Abstract available


  133. MARTINEZ L, Thames E, Kim J, Chaudhuri G, et al
    Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis.
    BMC Cancer. 2016;16:559.
    PubMed     Text format     Abstract available


  134. KUHLMANN JD, Bankfalvi A, Schmid KW, Callies R, et al
    Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.
    BMC Cancer. 2016;16:618.
    PubMed     Text format     Abstract available


  135. HUBER MC, Mall R, Braselmann H, Feuchtinger A, et al
    uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    BMC Cancer. 2016;16:615.
    PubMed     Text format     Abstract available


  136. JIN X, Jiang YZ, Chen S, Yu KD, et al
    A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
    BMC Cancer. 2016;16:606.
    PubMed     Text format     Abstract available


  137. MC MENAMIN UC, Murray LJ, Hughes CM, Cardwell CR, et al
    Statin use and breast cancer survival: a nationwide cohort study in Scotland.
    BMC Cancer. 2016;16:600.
    PubMed     Text format     Abstract available


  138. MCNEELY ML, Campbell KL, Webster M, Kuusk U, et al
    Efficacy of night-time compression for breast cancer related lymphedema (LYNC): protocol for a multi-centre, randomized controlled efficacy trial.
    BMC Cancer. 2016;16:601.
    PubMed     Text format     Abstract available


  139. REZANIA S, Kammerer S, Li C, Steinecker-Frohnwieser B, et al
    Overexpression of KCNJ3 gene splice variants affects vital parameters of the malignant breast cancer cell line MCF-7 in an opposing manner.
    BMC Cancer. 2016;16:628.
    PubMed     Text format     Abstract available


  140. RUDOLPH M, Anzeneder T, Schulz A, Beckmann G, et al
    AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    BMC Cancer. 2016;16:622.
    PubMed     Text format     Abstract available


  141. RASHID MU, Muhammad N, Bajwa S, Faisal S, et al
    High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    BMC Cancer. 2016;16:673.
    PubMed     Text format     Abstract available


  142. KRSTIC M, Macmillan CD, Leong HS, Clifford AG, et al
    The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
    BMC Cancer. 2016;16:671.
    PubMed     Text format     Abstract available


  143. TAKAHASHI Y, Uruga H, Fujii T, Mochizuki S, et al
    Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy in a patient with recurrent breast cancer: a case report.
    BMC Cancer. 2016;16:666.
    PubMed     Text format     Abstract available


  144. DIERSSEN-SOTOS T, Gomez-Acebo I, de Pedro M, Perez-Gomez B, et al
    Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.
    BMC Cancer. 2016;16:660.
    PubMed     Text format     Abstract available


  145. GUERRA E, Cimadamore A, Simeone P, Vacca G, et al
    p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.
    BMC Cancer. 2016;16:649.
    PubMed     Text format     Abstract available


  146. PROSKURINA AS, Gvozdeva TS, Potter EA, Dolgova EV, et al
    Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
    BMC Cancer. 2016;16:651.
    PubMed     Text format     Abstract available


  147. GREGOIRE JM, Fleury L, Salazar-Cardozo C, Alby F, et al
    Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells.
    BMC Cancer. 2016;16:700.
    PubMed     Text format     Abstract available


  148. CHEN CY, Yang CY, Chen YC, Shih CW, et al
    Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer.
    BMC Cancer. 2016;16:697.
    PubMed     Text format     Abstract available


  149. ZHOU K, Wang D, He X, Huo L, et al
    Effectiveness of a multimodal standard nursing program on health-related quality of life in Chinese mainland female patients with breast cancer: protocol for a single-blind cluster randomized controlled trial.
    BMC Cancer. 2016;16:698.
    PubMed     Text format     Abstract available


  150. SHOU J, Zhang Z, Lai Y, Chen Z, et al
    Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
    BMC Cancer. 2016;16:687.
    PubMed     Text format     Abstract available


  151. MENESES-ECHAVEZ JF, Jimenez EG, Rio-Valle JS, Correa-Bautista JE, et al
    The insulin-like growth factor system is modulated by exercise in breast cancer survivors: a systematic review and meta-analysis.
    BMC Cancer. 2016;16:682.
    PubMed     Text format     Abstract available


  152. KUBECEK O, Soukup T, Paulik A, Kopecky J, et al
    Dermatomyositis with anti-TIF-1gamma antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
    BMC Cancer. 2016;16:684.
    PubMed     Text format     Abstract available


  153. MIN L, Zhang C, Ma R, Li X, et al
    Overexpression of synuclein-gamma predicts lack of benefit from radiotherapy for breast cancer patients.
    BMC Cancer. 2016;16:717.
    PubMed     Text format     Abstract available


  154. HENNIGS A, Riedel F, Gondos A, Sinn P, et al
    Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.
    BMC Cancer. 2016;16:734.
    PubMed     Text format     Abstract available


  155. ROMERO A, Tora-Rocamora I, Bare M, Barata T, et al
    Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs.
    BMC Cancer. 2016;16:735.
    PubMed     Text format     Abstract available


  156. HONG R, Ma F, Zhang W, Yu X, et al
    53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    BMC Cancer. 2016;16:725.
    PubMed     Text format     Abstract available


  157. OH K, Lee OY, Park Y, Seo MW, et al
    IL-1beta induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
    BMC Cancer. 2016;16:724.
    PubMed     Text format     Abstract available


  158. CORDINA-DUVERGER E, Truong T, Anger A, Sanchez M, et al
    Weight and weight changes throughout life and postmenopausal breast cancer risk: a case-control study in France.
    BMC Cancer. 2016;16:761.
    PubMed     Text format     Abstract available


  159. HADAD SM, Jordan LB, Roy PG, Purdie CA, et al
    A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
    BMC Cancer. 2016;16:745.
    PubMed     Text format     Abstract available


  160. MATSUMURA K, Nakata S, Taniguchi K, Ii H, et al
    Depletion of gamma-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation.
    BMC Cancer. 2016;16:748.
    PubMed     Text format     Abstract available


    January 2015
  161. FRAMARINO-DEI-MALATESTA M, Perrone G, Giancotti A, Ventriglia F, et al
    Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.
    BMC Cancer. 2015;15:951.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: